Sabril (SAY-bril, vigabatrin) is a new oral therapy for refractory epilepsy and infantile spasms
Sabril (SAY-bril, vigabatrin) is a new oral therapy for refractory epilepsy and infantile spasms.
Use of this drug will be restricted because it can cause permanent vision loss in about 30% of patients.
This vision loss is a progressive narrowing of the visual field. The risk increases with higher doses or longer duration.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote